<DOC>
	<DOCNO>NCT02706873</DOCNO>
	<brief_summary>This randomize , double-blind study compare ABT-494 monotherapy Methotrexate ( MTX ) monotherapy MTX-naïve subject moderately severely active rheumatoid arthritis</brief_summary>
	<brief_title>A Study Compare ABT-494 Monotherapy Methotrexate Monotherapy Subjects With Rheumatoid Arthritis ( RA ) Who Have Not Previously Taken Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Duration symptom consistent RA ≥ 6 week also fulfill 2010 ACR/EULAR classification criterion RA . Naïve Methotrexate ( MTX ) , already MTX , receive 3 weekly MTX dose requirement complete 4week MTX washout first dose study drug . Subjects prior exposure conventional synthetic diseasemodifying antirheumatic drug ( csDMARDs ) MTX may enrol complete washout period . Subject meet follow minimum disease activity criterion : great equal 6 swollen joint ( base 66 joint count ) great equal 6 tender joint ( base 68 joint count ) Screening Baseline Visits . great equal 1 bone erosion xray ( local reading ) OR absence document bone erosion , positive rheumatoid factor positive anticyclic citrullinated peptide autoantibody require Screening . Intolerant Methotrexate ( MTX ) . Prior exposure Janus kinase ( JAK ) inhibitor ( include limit tofacitinib , baricitinib , filgotinib ) . Prior exposure biologic diseasemodifying antirheumatic drug ( bDMARDs ) . History arthritis onset prior age 17 year current diagnosis , inflammatory joint disease RA ( include limit gout , systemic lupus erythematosus , psoriatic arthritis , axial spondyloarthritis include ankylose spondylitis nonradiographic axial SpA , reactive arthritis , overlap connective tissue disease , scleroderma , polymyositis , dermatomyositis , fibromyalgia [ currently active symptom ] . Current diagnosis secondary Sjogren 's Syndrome permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Musculoskeletal disease</keyword>
	<keyword>Anti-inflammatory agent</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Joint disease</keyword>
	<keyword>Antirheumatic agent</keyword>
</DOC>